Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 6, 2007BloodOpen Access

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

View Full Paper
Ask AI
Bookmark
Share

Authors

EHElizabeth O. HexnerCSCynthia SerdikoffMJMahfuza Jan

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hexner et al. (2007) studied this question.

synapsesocial.com/papers/6a7dab98a76b9ebabb045076https://doi.org/10.1182/blood-2007-04-083402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors2002 · 4,422 citations
  2. 2Expression of Jak2V617F causes a polycythemia vera–like disease with associated myelofibrosis in a murine bone marrow transplant model2006 · 478 citations
  3. 3Chromosome Studies on Normal and Leukemic Human Leukocytes1960 · 1,076 citations
  4. 4Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia2004 · 629 citations
  5. 5Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia2001 · 218 citations